Updated

Updated · MarketWatch · Apr 28

Charles River Laboratories stock falls 2.59% to $166.79, underperforming competitors

Updated

Updated · MarketWatch · Apr 28

Charles River Laboratories stock falls 2.59% to $166.79, underperforming competitors

10 articles · Updated · MarketWatch · Apr 28

The company's share price ended Tuesday at $166.79, snapping a two-day winning streak and closing 27.13% below its 52-week high of $228.88 reached on January 13.
This decline occurred during a broadly negative trading session, with the S&P 500 dropping 0.49% and the Dow Jones falling 0.05%.
Charles River Laboratories' performance was mixed compared to peers, as Labcorp Holdings, Alnylam Pharmaceuticals, and Bio-Techne also recorded losses, reflecting sector-wide market weakness.

Is AI the real threat to Charles River, or is its stock drop just market noise?

What must Charles River's May 6 earnings report prove to calm investor fears?

Is Charles River's divestment strategy a masterstroke or a retreat from new technology?

Can the BIOSECURE Act shield US research firms from the looming threat of AI?

A CEO says AI won't replace animal testing. Is the market right to disagree?

Can a secure primate supply chain protect a research firm in the age of AI?